Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Public ClinicalTrials.gov record NCT04341116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Study identification
- NCT ID
- NCT04341116
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Interventions
- TJ003234 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2020
- Primary completion
- Feb 6, 2022
- Completion
- Feb 6, 2022
- Last update posted
- May 5, 2023
2020 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas | Little Rock | Arkansas | 72205 | — |
| Olive View-UCLA Medical Center | Sylmar | California | 91342 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| The GW Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | — |
| University of Miami | Miami | Florida | 33146 | — |
| OSF Healthcare Saint Francis Medical Center | Peoria | Illinois | 61637 | — |
| Indiana University Health | Indianapolis | Indiana | 46202 | — |
| Medpharmics, LLC | Metairie | Louisiana | 70006 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| University Medical Center of Southern Nevada | Las Vegas | Nevada | 89102 | — |
| UNM Hospitals | Albuquerque | New Mexico | 87106 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04341116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04341116 live on ClinicalTrials.gov.